A multisystem, cardio-renal investigation of post-COVID-19 illness.
СтатьяПоддержка исследования: вне правительства СШАНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Morrow Andrew J, Sykes Robert, McIntosh Alasdair, Kamdar Anna, Bagot Catherine, Bayes Hannah K, Blyth Kevin G, Briscoe Michael, Bulluck Heerajnarain, Carrick David, Church Colin, Corcoran David, Findlay Iain, Gibson Vivienne B, Gillespie Lynsey, Grieve Douglas, Hall Barrientos Pauline, Ho Antonia, Lang Ninian N, Lennie Vera, Lowe David J, Macfarlane Peter W, Mark Patrick B, Mayne Kaitlin J, McConnachie Alex, McGeoch Ross, McGinley Christopher, McKee Connor, Nordin Sabrina, Payne Alexander, Rankin Alastair J, Robertson Keith E, Roditi Giles, Ryan Nicola, Sattar Naveed, Allwood-Spiers Sarah, Stobo David, Touyz Rhian M, Veldtman Gruschen, Watkins Stuart, Weeden Sarah, Weir Robin A, Welsh Paul, Wereski Ryan, CISCO-19 Consortium, Mangion Kenneth, Berry Colin
Аннотация
The pathophysiology and trajectory of post-Coronavirus Disease 2019 (COVID-19) syndrome is uncertain. To clarify multisystem involvement, we undertook a prospective cohort study including patients who had been hospitalized with COVID-19 (ClinicalTrials.gov ID NCT04403607 ). Serial blood biomarkers, digital electrocardiography and patient-reported outcome measures were obtained in-hospital and at 28-60 days post-discharge when multisystem imaging using chest computed tomography with pulmonary and coronary angiography and cardio-renal magnetic resonance imaging was also obtained. Longer-term clinical outcomes were assessed using electronic health records. Compared to controls (n = 29), at 28-60 days post-discharge, people with COVID-19 (n = 159; mean age, 55 years; 43% female) had persisting evidence of cardio-renal involvement and hemostasis pathway activation. The adjudicated likelihood of myocarditis was 'very likely' in 21 (13%) patients, 'probable' in 65 (41%) patients, 'unlikely' in 56 (35%) patients and 'not present' in 17 (11%) patients. At 28-60 days post-discharge, COVID-19 was associated with worse health-related quality of life (EQ-5D-5L score 0.77 (0.23) versus 0.87 (0.20)), anxiety and depression (PHQ-4 total score 3.59 (3.71) versus 1.28 (2.67)) and aerobic exercise capacity reflected by predicted maximal oxygen utilization (20.0 (7.6) versus 29.5 (8.0) ml/kg/min) (all P < 0.01). During follow-up (mean, 450 days), 24 (15%) patients and two (7%) controls died or were rehospitalized, and 108 (68%) patients and seven (26%) controls received outpatient secondary care (P = 0.017). The illness trajectory of patients after hospitalization with COVID-19 includes persisting multisystem abnormalities and health impairments that could lead to substantial demand on healthcare services in the future.